Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China’s Hengrui In-Licenses AMD Antibody Program From X-Body Biosciences

This article was originally published in PharmAsia News

Executive Summary

Hengrui becomes the first Chinese manufacturer to in-license an early stage MAb from a Western biopharma as it looks to develop an age-related macular degeneration therapy that could compete with Novartis/Roche’s Lucentis and Bayer/Regeneron’s Eylea.

You may also be interested in...

Challenging Lucentis: Eylea’s Early Progress Prompts $250 Mil.-$300 Mil. Sales Forecast For 2012

Eylea manufacturer Regeneron says the new treatment for wet AMD is being reimbursed by all regional Medicare claims contractors.

Jiangsu Hengrui Shifts From Generic Supplier To Innovative Company; Analysts See Shades Of Takeda In Transformation

SHANGHAI - Jiangsu Hengrui Medicine Co. Ltd. seeks to transform itself from a generic company to an innovative one and tap into overseas markets. The move has prompted Chinese analysts to draw comparisons to the business models of Japan's largest pharma and to predict that Jiangsu Hengrui could become China's version of Takeda Pharmaceutical Co. Ltd.

Boehringer Bets On External Innovation In Post-COVID China

From cell therapy to digital health, from fast follower to innovator, China continues to gain traction with global health companies, underscored by its early emergence from the global pandemic and focus on certain technologies, with Boehringer Ingelheim the latest to be attracted.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts